IDEAYA Biosciences, Inc. IDYA
31.33 USD -0.31 (-0.98%)
At closeNov 3, 2026, 4:01 PM EST
31.33 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
31.08 Day range 32.49
26.81 52-week range 42.68
- YTD
- -9.37%
- 1 year
- -0.10%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 51.92 +65.7% upside
Now 31.33
- Target (low)
- 31.00
- Target (mean)
- 51.92
- Target (high)
- 65.00
Ratings (0m) 16 15 buy · 1 hold · 0 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 16
- 1 month ago 14
- 2 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.14 | -1.44 – -0.82 | -0.94 | -20.9% | 19.72M | +81.3% | 14 |
| Next quarter | -1.21 | -1.41 – -1.04 | -1.11 | -9.0% | 11.98M | +82.6% | 6 |
| Current year | -4.59 | -5.20 – -4.02 | -1.28 | -258.4% | 41.01M | -81.3% | 14 |
| Next year | -4.11 | -5.43 – -1.78 | -4.59 | +10.3% | 118.30M | +188.5% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Oct 14, 2026 | Stifel | Initiated | — | Buy |
| Sep 9, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 1, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Aug 5, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 5, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jun 12, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 2, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| May 7, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Apr 14, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 14, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 31, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 19, 2026 | Citigroup | Maintained | Buy | Buy |
| Feb 18, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Feb 18, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Feb 18, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 21, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jan 6, 2026 | Truist Securities | Maintained | Buy | Buy |
| Nov 24, 2025 | Truist Securities | Initiated | — | Buy |
| Nov 11, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Oct 23, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 21, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 21, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 21, 2025 | BTIG | Reiterated | Buy | Buy |
| Sep 18, 2025 | Guggenheim | Initiated | — | Buy |
